KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jul 31, 2026. Filed Sep 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2026 · Filed Sep 14, 2026
KMTS$29.55-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
| July 31, | April 30, | |
|---|---|---|
| 2026 | 2026 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $68,558 | $99,710 |
| Short-term investments | 130,353 | 96,724 |
| Accounts receivable, net | 15,406 | 14,542 |
| Disposable medical equipment supplies | 7,438 | 6,706 |
| Prepaid expenses and other current assets | 4,518 | 4,677 |
| Total current assets | 226,273 | 222,359 |
| Long-term investments | 45,791 | 65,767 |
| Right-of-use assets | 3,263 | 3,364 |
| Deposits | 1,842 | 1,761 |
| Restricted cash | 334 | 334 |
| Property and equipment, net | 63,656 | 59,090 |
| Other long-term assets | 6,196 | 5,790 |
| Total assets | $347,355 | $358,465 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $25,961 | $27,295 |
| Accrued liabilities | 22,285 | 23,046 |
| Operating lease liabilities, current portion | 23 | 31 |
| Total current liabilities | 48,269 | 50,372 |
| Operating lease liabilities, net of current portion | 3,928 | 4,111 |
| Warrant liabilities | — | 1,369 |
| Other long-term liabilities | 306 | 306 |
| Long-term debt, net | 72,495 | 42,649 |
| Total liabilities | 124,998 | 98,807 |
| Commitments and contingencies (Note 12) | ||
| Shareholders’ equity | ||
| Common Shares, $1.00 par value; 100,000,000 shares authorized as of July 31, 2026 and April 30, 2026; 59,271,885 issued and outstanding as of July 31, 2026 and 58,383,924 shares issued and outstanding as of April 30, 2026 | 59,272 | 58,384 |
| Additional paid-in capital | 859,504 | 853,353 |
| Accumulated other comprehensive loss | (471) | (218) |
| Accumulated deficit | (695,948) | (651,861) |
| Total shareholders’ equity | 222,357 | 259,658 |
| Total liabilities and shareholders’ equity | $347,355 | $358,465 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.